2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Great Hall BC
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult, Pediatric
PAPER

383 Targeting Bruton's tyrosine kinase to overcome venetoclax resistance in acute myeloid leuekmia, from bench to bedside

Guo-Pan Yu, MD, Dandan Chen2, Zhao Yin3, Jiacheng Xu4, Jing Huang5, Yuanyuan Du6, Zhao Yin7, Liling Zheng8, Xiaoting Zhang9, Rong Hu10, Shuang Liu11, Qing Zhang12
1 Nanfang Hospital, Southern Medical University, Guangzhou, China, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, China
5 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
6 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
7 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
8 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
9 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
10 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
11 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
12 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China

Abstract: Bruton's tyrosine kinase (BTK) plays an important role in drug resistance in acute myeloid leukemia (AML). More and more patients are reported to relapse after the treatment of BCL-2 specific inhibitor venetoclax (Ven) based therapy in AML. However, whether BTK is associated with Ven resistance in AML remains unknown. In the preclinical study, we induced Ven-resistant cells, and found that the expression of BTK in Ven-resistant cells presented significantly increasing compared to Ven-sensitive ones. Meanwhile, the patients relapsed after Ven-based therapy had higher BTK expression. When BTK was inhibited by gene knockdown or BTK inhibitor Ibrutinib, the resistance to Ven in AML cells was partly overcome. Also, Ibrutinib synergized with Ven in killing effect of Ven-resistant cells in both cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mice, without obvious organ damage, and prolonged the survival of mice. Mechanism study showed BTK activated NF-κB signaling pathway and then strengthened the expression of MCL-1 and BCL-xL to induce Ven resistance. With the agreement of the ethics committee, we further conducted an exploitative trial to treat Ven-resistant AML patients with BTK inhibitor Zanubrutinib combined with Ven (ZV). Five frail patients with relapsed/refractory AML (de novo 2, secondary 3), the ECOG score of 3-4, median age of 69(58-81) years old, median bone marrow blast of 24%(13.5%-74%), were enrolled. All the patients had median 5(3-6) lines exposure of Ven-based therapy. After one cycle of ZV treatment, all patients had more than 50% decrease in peripheral blast at day 15, and 3(60%) acquired response at day 30, as 2 with morphologic leukemia-free State (MLFS), 1 with partial response (PR). All the 3 responded patients underwent a progressing disease within 1-2 month, and could not respond to the second cycle of ZV treatment. All the 5 patients experienced relatively high quality of life, without fever, having better appetite and physical condition during the ZV treatment. No patients died of the treatment. In conclusion, overexpression of BTK could be an important factor of Ven resistance in AML via activation of NF-κB signaling. Targeting BTK might be a promising strategy to overcome Ven resistance with nice response and toleration. Further study should be initiated to guarantee.

Keywords: Bruton's tyrosine kinase, venetoclax, relapsed/refractory acute myeloid leukemia

Guo-Pan Yu, MD: No relevant conflicts of interest to declare.